Lymphomas are blood cancer which occur when the white blood cells grow abnormally. Lymphomas are categorized into three main types: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Hodgkin Lymphoma (Hodgkin's disease), and Non-Hodgkin Lymphoma (NHL). The Hodgkin Lymphoma (Hodgkin's disease) involves Reed-Sternberg cells and is less prevalent while the lymphomas which do not involve Reed-Sternberg cells are categorized under Non-Hodgkin Lymphoma (NHL) and are more prevalent then Hodgkin Lymphomas.
Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) non-Hodgkin lymphoma (NHL) which affects the B-lymphocytes and can develop either in lymph nodes or in ‘extranodal sites’ (areas outside the lymph nodes). When DLBCL reappears or grows again after a period of remission, it is called as ‘relapsed’ while the term ‘refractory’ is used to define the situation when the lymphoma does not respond to treatment
The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at US$ 1,364 million in 2021 and is expected to exhibit a CAGR of 4.2% over the forecast period (2021-2028).
Figure 1. Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Share (%) in Terms of Value, By Region, 2020
Significant prevalence of diffuse large B-cell lymphoma is expected to propel the market growth over the forecast period
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma (NHL). According to the Lymphoma Research Foundation, a U.S.-based nonprofit organization, more than 18,000 new cases of diffuse large B-cell lymphoma (DLBCL) are diagnosed every year in the U.S.
Moreover, the Surveillance, Epidemiology, and End Results (SEER) Program, which provides information on cancer statistics among the U.S. population, estimated the percent of cases diagnosed according to the stages which is given in graph below
Figure 2. Diffuse Large B-cell Lymphoma Cases by Stages in the U.S.
Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities is expected to drive the market growth over the forecast period
Market players are focusing on approvals for relapsed or refractory diffuse large B-cell lymphoma therapeutics from regulatory authorities which is expected to accelerate the market growth. On February 8, 2021, Bristol Myers Squibb, a pharmaceutical company, received approval for lisocabtagene maraleucel (liso-cel, Breyanzi), chimeric antigen receptor (CAR) T-cell therapy, indicated for diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B, in patients who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Report Coverage
||Market Size in 2020:
||US$ 1,364 Mn
|Historical Data for:
||2017 to 2020
||2020 to 2027
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 1,975.5 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Others.
- By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies.
MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG
- Increasing prevalence of diffuse large B-cell lymphoma
- Increasing approval of therapeutics for relapsed or refractory diffuse large B-cell lymphoma by regulatory authorities
|Restraints & Challenges:
- Side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma
Global Relapsed or Refractory Diffuse Large B-cell Lymphoma Market – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 132 million cases and 2.87 million deaths due to coronavirus disease (COVID-19) were reported till April 7, 2021 across the globe.
Rapidly increasing cases of COVID-19 caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.
According to National Center for Biotechnology Information (NCBI), April 29, 2020, many clinical trials suspended the trial enrollment, in order to minimize the risk of contracting COVID-19 and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Furthermore, travel restrictions, patient concerns of contracting coronavirus infection, and others are some of the factors responsible for the withdrawal of patients from the clinical trial.
Relapsed or Refractory Diffuse Large B-cell Lymphoma Market Restraint
However, side effects associated with therapeutics for relapsed or refractory diffuse large B-cell lymphoma are expected to hinder the market growth. For example, common adverse reactions occurring in diffuse large B-cell lymphoma patients when treated with MONJUVI (tafasitamab-cxix) are listed below:
- Infusion reaction such as headache, shortness of breath, and chills during the infusion of MONJUVI
- Low blood cell counts of red blood cells, white blood cells, and platelets is common when patients are treated with MONJUVI which can become life threatening
- The patients can acquire life threatening infections. Patients should inform their doctors if they get fever of 100.4°F (38°C) or above
Apart from the above stated adverse events, common side effects associated with MONJUVI administration includes diarrhea, cough, fever, decreased appetite, respiratory tract infection, swelling of lower legs or hands, and fatigue.
Major players operating in the global relapsed or refractory diffuse large B-cell lymphoma market include MorphoSys US Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F. Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., and Novartis AG.